Until yesterday, biopharmaceutical research companies were allowed to disable comments from users on certain Facebook pages. This helped companies ensure that those pages were sources of accurate information, though it meant they were removing some ability to engage the public in a dialogue.
Most Recent Posts
Austin Frakt over at the Incidental Economist weighs in on the recent JAMA study on the value of the Medicare Part D program. The JAMA study found that Part D saves Medicare about $1,200 per year in hospital, nursing home and other costs for each senior who previously lacked comprehensive prescription drug coverage.
Last week we were talking a lot about the JAMA study showing how proper use of prescription medicines by Part D beneficiaries is helping to reduce overall Medicare non-drug medical expenditures.
Yesterday, we were talking about a new study in the Journal of the American Medical Association (JAMA) that found that proper use of prescription medicines by Part D beneficiaries is helping to reduce non-drug medical expenditures in Medicare overall. The core of the JAMA study:
Once again, we're looking at the value of access to prescription medicines today, fueled by a study in today's Journal of the American Medical Association (subscription required).
A recent AP LifeGoesStrong.com poll found that baby boomers' (born between 1946 and 1964) health concerns are focused mostly on possible cancers and memory loss. Obviously, these are important concerns for everyone as they age.
A recent article lauding a so-called "looming wave of new generic pills," like many similar articles, fails to paint the bigger picture: that generics, while an important part of the healthcare system, ultimately play a limited role for patients.
A few weeks ago, as I was visiting my family, I took one look at my two-year-old niece and said to my sister, "Mary's diaper needs changing."